机构：[1]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院四川省肿瘤医院[2]Radiotherapy, Chengdu Medical College, Chengdu, China
Sichuan Science and technology program (fund) [2021JDRC0146]; Immunoradiotherapy research fund project of radiotherapy and Oncology Society of Chinese Medical Association
第一作者机构：[1]Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
推荐引用方式(GB/T 7714)：
Zhang Q.,Feng M.,Chen L.,et al.Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer[J].ANNALS OF ONCOLOGY.2021,32:S795-S795.doi:10.1016/j.annonc.2021.08.1292.
APA：
Zhang, Q.,Feng, M.,Chen, L.,Yan, L.&Huang, Y..(2021).Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer.ANNALS OF ONCOLOGY,32,
MLA：
Zhang, Q.,et al."Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer".ANNALS OF ONCOLOGY 32.(2021):S795-S795
医学